Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to examine the prevalence of activation cluster adverse events (AC-AEs) in youths treated with the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for anxiety and the relationship of AC-AEs to SSRI blood levels. METHODS: Data from the Research Units on Pediatric Psychopharmacology (RUPP) Anxiety Study were examined for 45 youths (22 active fluvoxamine, 23 placebo) treated for Diagnostic and Statistical Manual for Mental Disorders, 4(th) edition (DSM-IV) anxiety disorders at the Johns Hopkins University site with an 8-week forced-flexible titration schedule. As part of the double-blind placebo-controlled trial, AC-AEs were recorded by clinicians at weekly patient visits. AC-AEs were defined as hyperactivity, activation, and disinhibition. Demographic characteristics, daily doses, and week-8 blood levels were examined in relation to the presence of AC-AEs. The prevalence of AC-AE and time to first event were established for those who experienced this side effect. RESULTS: AC-AEs were found in 10 of 22 participants (45%) receiving fluvoxamine and only 1 of 23 in the placebo group (4%). The onset of AC-AEs occurred from week 1 to week 8, with the majority occurring at or before week 4. The mean fluvoxamine blood level at week 8 in subjects with AC-AEs was higher than in subjects without AC-AEs (n = 16, t = -2.61, p = 0.04). Neither the age of the participants nor family history of bipolar or anxiety disorder differed between those who did and did not develop an AC-AE. CONCLUSIONS: AC-AEs were common side effects of fluvoxamine, often appeared during the first 8 weeks of treatment, and were associated with higher fluvoxamine blood levels. Close monitoring for AC-AEs, not only when initiating SSRI treatment but also throughout dose titration, is recommended for early identification of activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716 · cited 2×
“Additional criteria were: clinically important symptoms according to the Pediatric Anxiety Rating Scale (PARS) (Research Units for Pediatric Psychopharmacology Anxiety Study Group 2002), score under 60 on the Children’s Global Assessment Scale (CGAS) indicating functional impairment (Shaffer et al. 1983), and child an…”
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Self-citationThe Pediatric Anxiety Rating Scale (PARS): development and psychometric properties
P, T. R. U. O. P. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00006 · Cited by 532
Garland, E. J., & Baerg, E. A. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601750284090 · Cited by 80 · cited 1×
“The role of the frontal lobe in SSRI-induced behavioral activation, disin-hibition, and SSRI-induced amotivational syndrome or apa-thy is not known, although the frontal lobe may mediate different adverse events (Hoehn-Saric et al. 1991; Garland and Baerg 2001; Reinblatt and Riddle 2006).”
Cited by
The Lancet Commission on the future of care and clinical research in autism
Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., de Vries, P. J., Dissanayake, C., Divan, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01541-5 · Cited by 924
Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths
Leibenluft, E. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050766 · Cited by 565
Strawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., & Rynn, M. A. (2015) · Depression and Anxiety · doi:10.1002/da.22329 · Cited by 183
“1% in adolescents experience activation in randomized, controlled trials of antidepressants,[38] although depending on data collection techniques, considerable variability in observed rates of activation exists.[36, 39, 40] Although these rates of activation are consistent with the rates reported herein (mean: 21.”
BackgroundResultAnxiety Disorders and Obsessive-Compulsive Disorder in Individuals with Autism Spectrum Disorder
Postorino, V., Kerns, C. M., Vivanti, G., Bradshaw, J., Siracusano, M., & Mazzone, L. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0846-y · Cited by 186
A Systematic Review of Treatments for Anxiety in Youth with Autism Spectrum Disorders
Vasa, R. A., Carroll, L. M., Nozzolillo, A. A., Mahajan, R., Mazurek, M. O., Bennett, A. E., Wink, L. K., & Bernal, M. P. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2184-9 · Cited by 168
“Behavioral activation is a well-known side effect of SSRIs in children and is characterized by a cluster of symptoms including increased activity level, impulsivity, insomnia, or disinhibition without manic symptoms (Reinblatt et al. 2009).”
Background
Metadata
- Authors
- Reinblatt, S. P., dosReis, S., Walkup, J. T., & Riddle, M. A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-04
- Volume
- 19
- Issue
- 2
- Pages
- 119-126
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1974610592
- Cited by
- 81
- References
- 4
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. https://app.cochat.ai/papers/10.1089/cap.2008.040
- The paper
- Reinblatt, S. P., dosReis, S., Walkup, J. T., & Riddle, M. A. (2009). Activation Adverse Events Induced by the Selective Serotonin Reuptake Inhibitor Fluvoxamine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2008.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.